Evidence map›Paper›PMID 38261153›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2024

Validating the usefulness of Sudoscan in ATTRv: a single centre experience.

Elena Moreno-Moraleda, Juan González-Moreno, Eugenia Cisneros-Barroso, María Antonia Ribot-Sansó, Tomás Ripoll-Vera, Cristina Descals, Mercedes Uson, Joan Carles Montalà, Antoni Figuerola, Adrián Rodríguez and 1 more

Open access · greenAbstract readValidation Study
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Elena Moreno-MoraledaUniversitat de Les Illes Balears, Palma, Spain.
Juan González-MorenoInternal Medicine, Hospital Universitario Son Llàtzer, Palma, Spain.
Eugenia Cisneros-BarrosoBalearic Research Group in Genetic Cardiopathies, Sudden Death and TTR Amyloidosis, Instituto de Investigación Sanitaria de Las Islas Baleares (IdISBa), Palma, Spain. euge0086@gmail.com.ORCID http://orcid.org/0000-0002-4109-4635
María Antonia Ribot-SansóInternal Medicine, Hospital Universitario Son Llàtzer, Palma, Spain.
Tomás Ripoll-VeraBalearic Research Group in Genetic Cardiopathies, Sudden Death and TTR Amyloidosis, Instituto de Investigación Sanitaria de Las Islas Baleares (IdISBa), Palma, Spain.
Cristina DescalsBalearic Research Group in Genetic Cardiopathies, Sudden Death and TTR Amyloidosis, Instituto de Investigación Sanitaria de Las Islas Baleares (IdISBa), Palma, Spain.
Mercedes UsonBalearic Research Group in Genetic Cardiopathies, Sudden Death and TTR Amyloidosis, Instituto de Investigación Sanitaria de Las Islas Baleares (IdISBa), Palma, Spain.
Joan Carles MontalàBalearic Research Group in Genetic Cardiopathies, Sudden Death and TTR Amyloidosis, Instituto de Investigación Sanitaria de Las Islas Baleares (IdISBa), Palma, Spain.
Antoni FiguerolaBalearic Research Group in Genetic Cardiopathies, Sudden Death and TTR Amyloidosis, Instituto de Investigación Sanitaria de Las Islas Baleares (IdISBa), Palma, Spain.
Adrián RodríguezBalearic Research Group in Genetic Cardiopathies, Sudden Death and TTR Amyloidosis, Instituto de Investigación Sanitaria de Las Islas Baleares (IdISBa), Palma, Spain.
Inés LosadaInternal Medicine, Hospital Universitario Son Llàtzer, Palma, Spain.
Hospital Son Llatzer · ESHealth Research Institute of the Balearic Islands · ESFundació Universitat-Empresa de les Illes Balears · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVariant transthyretin amyloidosis (ATTRv) can cause sensorimotor and autonomic neuropathy. Objective quantification of sudomotor function may be essential for early diagnosis and early initiation of treatment. The aim of this study is to evaluate the diagnostic value of the Sudoscan® in ATTRv.

methodsElectrochemical skin conductance (ESC) was measured in V30M ATTRv patients, asymtomatic V30M carriers and healthy controls. Comparisons between the three groups were made using the Kruskal-Wallis test, and ROC curves were used to estimate the discriminatory power of ESC values between groups.

resultsESC was measured in 52 ATTRv patients, 107 asymptomatic carriers and 40 healthy controls. ESC was significantly lower in ATTRv patients compared to asymptomatic carriers and healthy controls in both feet and hands; median values are as follows: 40 µS, 78 µS and 81 µS, respectively (p < 0.001), and 53 µS, 69 µS and 74 µS, respectively (p < 0.001). ESC in feet < 70.5 µS had a sensitivity of 89.7% and specificity of 84.6% to discriminate asymptomatic carriers from patients with ATTRv.

conclusionThe determination of ESC by Sudoscan® is a rapid, noninvasive and easily reproducible technique capable of discriminating patients with ATTRv from asymptomatic carriers and healthy controls with adequate sensitivity and specificity.

Indexed as

Amyloid Neuropathies, FamilialGalvanic Skin ResponseAdultAgedFemaleFootHandHumansMaleMiddle AgedPrealbuminSensitivity and SpecificityPrealbuminAutonomic dysfunctionEarly diagnosisElectrochemical skin conductanceRare diseaseVariant transthyretin amyloidosis

Identifiers

PMID38261153
OpenAlexW4391132338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.